Polatuzumab vedotin (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Polatuzumab vedotin" in English language version.

refsWebsite

Global rank English rank

19web.archive.org

1^st place

4fda.gov

447^th place

338^th place

3gene.com

low place

2medicines.org.uk

3,823^rd place

2,387^th place

2handle.net

102^nd place

76^th place

1tga.gov.au

3,984^th place

2,622^nd place

1medsinfo.com.au

low place

1hres.ca

low place

1nih.gov

4^th place

1europa.eu

68^th place

117^th place

1onclive.com

low place

1pmlive.com

low place

1pharmaphorum.com

low place

1medcitynews.com

low place

1ama-assn.org

3,257^th place

3,398^th place

ama-assn.org

searchusan.ama-assn.org

"Archived copy" (PDF). Archived (PDF) from the original on 22 April 2023. Retrieved 22 April 2023.{{cite web}}: CS1 maint: archived copy as title (link)

europa.eu

ema.europa.eu

"Polivy EPAR". European Medicines Agency (EMA). 27 January 2020. Archived from the original on 27 October 2020. Retrieved 8 March 2020.

fda.gov

"FDA approves first chemoimmunotherapy regimen for patients with relapsed or refractory diffuse large B-cell lymphoma" (Press release). U.S. Food and Drug Administration (FDA). 10 June 2019. Archived from the original on 25 November 2019. Retrieved 24 November 2019. This article incorporates text from this source, which is in the public domain.
"Drug Trials Snapshots: Polivy". U.S. Food and Drug Administration (FDA). 17 June 2019. Archived from the original on 25 November 2019. Retrieved 24 November 2019. This article incorporates text from this source, which is in the public domain.
"FDA approves polatuzumab vedotin-piiq for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma". U.S. Food and Drug Administration (FDA). 19 April 2023. Archived from the original on 21 April 2023. Retrieved 21 April 2023. This article incorporates text from this source, which is in the public domain.

accessdata.fda.gov

"Drug Approval Package: Polivy". U.S. Food and Drug Administration (FDA). 2 July 2019. Archived from the original on 30 October 2020. Retrieved 8 March 2020.

gene.com

"FDA Grants Genentech's Polivy Accelerated Approval for People With Previously Treated Aggressive Lymphoma" (Press release). Genentech. 10 June 2019. Archived from the original on 17 February 2023. Retrieved 22 April 2023.
"FDA Approves Genentech's Polivy in Combination With R-CHP for People With Certain Types of Previously Untreated Diffuse Large B-Cell Lymphoma" (Press release). Genentech. 19 April 2023. Archived from the original on 19 April 2023. Retrieved 22 April 2023.
"Polivy". Genentech. Archived from the original on 15 April 2023. Retrieved 15 July 2022.

handle.net

hdl.handle.net

World Health Organization (2013). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 70". WHO Drug Information. 27 (3). hdl:10665/331167.
World Health Organization (2014). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 71". WHO Drug Information. 28 (1). hdl:10665/331151.

hres.ca

hpr-rps.hres.ca

"Summary Basis of Decision (SBD) for Polivy". Health Canada. 23 October 2014. Archived from the original on 30 May 2022. Retrieved 29 May 2022.

medcitynews.com

Vinluan, Frank (19 April 2023). "New FDA Nod for Roche Drug Moves It to the Front Line in Treating Blood Cancer". MedCity News. Archived from the original on 22 April 2023. Retrieved 20 April 2023.

medicines.org.uk

"Polivy 30 mg powder for concentrate for solution for infusion - Summary of Product Characteristics (SmPC)". (emc). 20 July 2022. Archived from the original on 22 April 2023. Retrieved 22 April 2023.
"Polivy 140 mg powder for concentrate for solution for infusion - Summary of Product Characteristics (SmPC)". (emc). 20 July 2022. Archived from the original on 12 July 2024. Retrieved 22 April 2023.

medsinfo.com.au

rss.medsinfo.com.au

"AUSTRALIAN PRODUCT INFORMATION – POLIVY (polatuzumab vedotin)". Archived from the original on 12 July 2024. Retrieved 12 July 2024.

nih.gov

dailymed.nlm.nih.gov

"Polivy- polatuzumab vedotin injection, powder, lyophilized, for solution". DailyMed. 14 November 2019. Archived from the original on 22 October 2020. Retrieved 23 August 2020.

onclive.com

"Polatuzumab Vedotin Plus R-CHP Recommended for EU Approval for Previously Untreated DLBCL". OneLive. 25 March 2022. Archived from the original on 19 April 2023. Retrieved 8 July 2022.

pharmaphorum.com

"Roche's Polivy gets FDA OK in frontline lymphoma". pharmaphorum. 20 April 2023. Archived from the original on 22 April 2023. Retrieved 20 April 2023.

pmlive.com

"Roche's Polivy recommended by NICE for lymphoma therapy". PMLive. 2 February 2023. Archived from the original on 9 February 2023. Retrieved 9 February 2023.

tga.gov.au

"Polivy Australian prescription medicine decision summary". Therapeutic Goods Administration (TGA). 13 December 2019. Archived from the original on 5 March 2020. Retrieved 23 August 2020.

web.archive.org

"Polivy Australian prescription medicine decision summary". Therapeutic Goods Administration (TGA). 13 December 2019. Archived from the original on 5 March 2020. Retrieved 23 August 2020.
"AUSTRALIAN PRODUCT INFORMATION – POLIVY (polatuzumab vedotin)". Archived from the original on 12 July 2024. Retrieved 12 July 2024.
"Summary Basis of Decision (SBD) for Polivy". Health Canada. 23 October 2014. Archived from the original on 30 May 2022. Retrieved 29 May 2022.
"Polivy 30 mg powder for concentrate for solution for infusion - Summary of Product Characteristics (SmPC)". (emc). 20 July 2022. Archived from the original on 22 April 2023. Retrieved 22 April 2023.
"Polivy 140 mg powder for concentrate for solution for infusion - Summary of Product Characteristics (SmPC)". (emc). 20 July 2022. Archived from the original on 12 July 2024. Retrieved 22 April 2023.
"Polivy- polatuzumab vedotin injection, powder, lyophilized, for solution". DailyMed. 14 November 2019. Archived from the original on 22 October 2020. Retrieved 23 August 2020.
"Polivy EPAR". European Medicines Agency (EMA). 27 January 2020. Archived from the original on 27 October 2020. Retrieved 8 March 2020.
"FDA Grants Genentech's Polivy Accelerated Approval for People With Previously Treated Aggressive Lymphoma" (Press release). Genentech. 10 June 2019. Archived from the original on 17 February 2023. Retrieved 22 April 2023.
"FDA approves first chemoimmunotherapy regimen for patients with relapsed or refractory diffuse large B-cell lymphoma" (Press release). U.S. Food and Drug Administration (FDA). 10 June 2019. Archived from the original on 25 November 2019. Retrieved 24 November 2019. This article incorporates text from this source, which is in the public domain.
"Drug Approval Package: Polivy". U.S. Food and Drug Administration (FDA). 2 July 2019. Archived from the original on 30 October 2020. Retrieved 8 March 2020.
"Drug Trials Snapshots: Polivy". U.S. Food and Drug Administration (FDA). 17 June 2019. Archived from the original on 25 November 2019. Retrieved 24 November 2019. This article incorporates text from this source, which is in the public domain.
"Polatuzumab Vedotin Plus R-CHP Recommended for EU Approval for Previously Untreated DLBCL". OneLive. 25 March 2022. Archived from the original on 19 April 2023. Retrieved 8 July 2022.
"Roche's Polivy recommended by NICE for lymphoma therapy". PMLive. 2 February 2023. Archived from the original on 9 February 2023. Retrieved 9 February 2023.
"FDA approves polatuzumab vedotin-piiq for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma". U.S. Food and Drug Administration (FDA). 19 April 2023. Archived from the original on 21 April 2023. Retrieved 21 April 2023. This article incorporates text from this source, which is in the public domain.
"Roche's Polivy gets FDA OK in frontline lymphoma". pharmaphorum. 20 April 2023. Archived from the original on 22 April 2023. Retrieved 20 April 2023.
Vinluan, Frank (19 April 2023). "New FDA Nod for Roche Drug Moves It to the Front Line in Treating Blood Cancer". MedCity News. Archived from the original on 22 April 2023. Retrieved 20 April 2023.
"FDA Approves Genentech's Polivy in Combination With R-CHP for People With Certain Types of Previously Untreated Diffuse Large B-Cell Lymphoma" (Press release). Genentech. 19 April 2023. Archived from the original on 19 April 2023. Retrieved 22 April 2023.
"Polivy". Genentech. Archived from the original on 15 April 2023. Retrieved 15 July 2022.
"Archived copy" (PDF). Archived (PDF) from the original on 22 April 2023. Retrieved 22 April 2023.{{cite web}}: CS1 maint: archived copy as title (link)